Kineta News December 1, 2022Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference >> December 1, 2022Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics ConferenceNovember 29, 2022Kineta to Participate in JMP Securities Hematology and Oncology Summit >> November 29, 2022Kineta to Participate in JMP Securities Hematology and Oncology SummitNovember 15, 2022Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors >> November 15, 2022Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
